Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
GRTX | US
0.00
2.78%
Healthcare
Biotechnology
30/06/2024
21/10/2024
0.06
0.06
0.06
0.06
Galera Therapeutics Inc. a clinical stage biopharmaceutical company focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419) a small molecule dismutase mimetic which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711 a dismutase mimetic product candidate which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern Pennsylvania.
View LessLow Debt to Equity (< 0.25)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
135.7%1 month
110.0%3 months
149.6%6 months
145.2%-
-
29.39
-0.01
0.07
-0.70
-
-
-24.81M
3.07M
3.07M
-
-
-
-
-1.06K
1.16
5.28
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.02
Range1M
0.03
Range3M
0.08
Rel. volume
0.34
Price X volume
2.38K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
22nd Century Group Inc | XXII | Biotechnology | 0.105 | 3.30M | 0.10% | n/a | -1072.15% |
Aptevo Therapeutics Inc | APVO | Biotechnology | 0.2389 | 3.21M | 20.35% | n/a | 112.59% |
NovaBay Pharmaceuticals Inc | NBY | Biotechnology | 0.6211 | 3.03M | -1.38% | n/a | -325.77% |
Hiru Corporation | HIRU | Biotechnology | 0.0016 | 3.02M | -15.79% | n/a | 263.27% |
SciSparc Ltd. Ordinary Shares | SPRC | Biotechnology | 0.29 | 3.00M | 26.53% | n/a | 1.00% |
Ensysce Biosciences Inc | ENSC | Biotechnology | 0.206 | 2.86M | 15.86% | n/a | 24.79% |
Cyclacel Pharmaceuticals Inc | CYCC | Biotechnology | 1.32 | 2.84M | 15.79% | n/a | 0.50% |
Phio Pharmaceuticals Corp | PHIO | Biotechnology | 3.18 | 2.74M | 9.28% | n/a | 0.00% |
Salarius Pharmaceuticals Inc | SLRX | Biotechnology | 1.82 | 2.62M | -9.45% | n/a | 0.00% |
ZVSA | ZVSA | Biotechnology | 2.3 | 2.47M | 0.00% | 0.00 | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.70 | 0.53 | Cheaper |
Ent. to Revenue | - | 3,967.00 | - |
PE Ratio | - | 41.03 | - |
Price to Book | 29.39 | 15.55 | Expensive |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 149.61 | 72.80 | Riskier |
Debt to Equity | -0.01 | -1.23 | Expensive |
Debt to Assets | 0.07 | 0.25 | Cheaper |
Market Cap | 3.07M | 3.66B | Emerging |